Drugs / AZD9164
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01096563 | Mar → Jun 2010 | — | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT01016951 | Dec 2009 → Jun 2010 | chronic obstructive pulmonary disease | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT00847249 | Feb → Apr 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00939211 | Jun → Nov 2009 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD9164 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00847249 ↗ |
| Known as | J3.232.015E | ChEMBL registry synonym — accepted as the source's own label CHEMBL1921904 ↗ |
| Action | Inhibit | “AZD9164, an M(3)-selective muscarinic antagonist” PMID 23098686 ↗ Oct 20121“Muscarinic acetylcholine receptor M3 antagonist” CHEMBL1921904 ↗ |
| Modality | Small molecule | — CHEMBL1921904 ↗ |
| Route | Inhaled | “Solution for nebulisation, inhaled” NCT00847249 ↗ |
| Target | CHRM3 | “Muscarinic acetylcholine receptor M3 antagonist” CHEMBL1921904 ↗ |